8-K

false
0000860730
0000860730
2026-01-27
2026-01-27

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 
8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 
January 27, 2026

 
 
HCA Healthcare, Inc.
(Exact name of Registrant as Specified in Its Charter)
 
 

Delaware

001-11239

27-3865930

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One Park Plaza

 

Nashville
, 
Tennessee

 

37203

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code:
 
(615)
 
344-9551

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.01 par value per share

 

HCA

 

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company 
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
☐
 

Item 2.02.  Results of Operations and Financial Condition.
On January 27, 2026, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2025, the text of which is set forth as 
Exhibit 99.1
.
Item 7.01.  Regulation FD Disclosure.
On January 27, 2026, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2025, the text of which is set forth as 
Exhibit 99.1
.
Item 8.01.  Other Events.
On January 27, 2026, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.
 
On January 27, 2026, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.78 per share of the Company’s common stock. The dividend will be paid on March 31, 2026 to stockholders of record at the close of business on March 17, 2026.
Item 9.01.  Financial Statements and Exhibits.
(d) Exhibits:
 

Exhibit 99.1

 

Press Release, dated January 27, 2026
 

Exhibit 104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

HCA HEALTHCARE, INC.

 

 

 

 

Date:

January 27, 2026

By:
 

/s/ Michael A. Marks

 

 

 

Michael A. Marks
Executive Vice President and Chief Financial Officer